摘要
目的探讨双抗治疗进展性脑卒中的效果。方法回顾性分析2014年5月至2019年5月呼伦贝尔市人民医院神经内科住院治疗的进展性脑卒中患者300例。给予双抗治疗的进展性卒中患者150例为观察组,给予单抗治疗的进展性卒中患者150例为对照组。通过上述治疗后,观察两组NIHSS评分、mRs评分、临床疗效及并发症发生率。结果观察组患者入院14 d NIHSS评分及mRs评分均较对照组明显下降,差异有统计学意义(t=24.225、22.364,P<0.05)。结论对于进展性卒中,双抗治疗优于单抗治疗。
Objective To explore the effect of double-antibody therapy in the treatment of progressive stroke.Methods A total of 300 patients with progressive stroke hospitalized in the Department of Neurology,Hulunbeier People′s Hospital from May 2014 to May 2019 were retrospectively analyzed.150 patients with progressive stroke were treated with double-antibody as the observation group,and 150 patients with progressive stroke were treated with monoclonal antibody as the control group.After the above treatment,NIHSS score and mRs score,clinical efficacy and complication rate were observed.Results Compared with the control group,the NIHSS score and mRs score in the observation group of 14 d of admission were significantly lower than those in the control group,and the differences were statistically significant(t=24.225,22.364,P<0.05).Conclusion Double-antibody therapy is superior to monoclonal antibody therapy for progressive stroke.
作者
孙海滨
包华
SUN Haibin;BAO Hua(Department of Neurology,Hulunbeier People′s Hospital in Inner Mongolia Autonomous Region,Hulunbeier 021008,China)
出处
《中国现代医生》
2021年第36期57-59,63,共4页
China Modern Doctor
